Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs

Author： Mentlein Rolf  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.1, 2005-01, pp. : 57-64

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incretin-Targeting Technologies for Type 2 Diabetes: Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 7, 2006-07 ,pp. : 3-7

Adis International

Access to resources Recommend Favorite

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

By Michel Martin  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 377, Iss. 3, 2008-05 ,pp. : 205-207

Springer Publishing Company

Access to resources Recommend Favorite

Metformin increases the plasma level of glucagon-like peptide-1 (GLP-1) and does not inhibit dipeptidyl peptidase-IV

By  

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite

The Therapeutic Potential of Inhibitors of Dipeptidyl Peptidase IV (DPP IV) and Related Proline-Specific Dipeptidyl Aminopeptidases

By  

Current Medicinal Chemistry, Vol. 12, Iss. 8, 2005-04 ,pp. : 971-998

Bentham Science Publishers

Access to resources Recommend Favorite